BIOCRYST PHARMACEUTICALS, INC. Income Taxes Paid
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Income Taxes Paid of $2.22 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2025-11-04
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2025-09-30 was $992.00K, a 175.56% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2025-06-30 was $1.23M, a 80.71% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2025-03-31 was $1.00K, a 99.46% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2024-12-31 was $378.00K.
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for fiscal 2024 was $1.60M, a 11.79% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for fiscal 2023 was $1.43M, a 59.51% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for fiscal 2022 was $3.54M, a 2901.69% increase from fiscal 2021.
- BIOCRYST PHARMACEUTICALS, INC. income taxes paid for fiscal 2021 was $118.00K.
| Period end | Income Taxes Paid 0 month | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $992.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.22M derived: sum of 2 quarters · filed 2025-11-04 | $2.22M 10-Q · filed 2025-11-04 | $2.60M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2025-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.23M 10-Q · filed 2025-08-05 | $1.61M derived: sum of 3 quarters · filed 2025-08-05 | $1.97M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2025-03-31 | $1.00K 10-Q · filed 2025-05-06 | $379.00K derived: sum of 2 quarters · filed 2025-05-06 | $739.00K derived: sum of 3 quarters · filed 2025-11-04 | $1.42M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $738.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.42M derived: sum of 3 quarters · filed 2025-11-04 | $1.60M 10-K · filed 2025-02-25 | |
| 2024-09-30 | $360.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.04M derived: sum of 2 quarters · filed 2025-11-04 | $1.23M 10-Q · filed 2025-11-04 | $1.22M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | $679.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $865.00K 10-Q · filed 2025-08-05 | $855.00K derived: sum of 3 quarters · filed 2025-08-05 | $1.17M derived: sum of 4 quarters · filed 2025-08-05 | |
| 2024-03-31 | $186.00K 10-Q · filed 2025-05-06 | $176.00K derived: sum of 2 quarters · filed 2025-05-06 | $494.00K derived: sum of 3 quarters · filed 2025-05-06 | $1.48M derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $308.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.29M derived: sum of 3 quarters · filed 2025-02-25 | $1.43M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.30M derived: sum of 2 quarters · filed 2024-11-05 | $1.44M 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $984.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.13M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $142.00K 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | $3.54M 10-K · filed 2025-02-25 | ||||
| 2021-12-31 | $118.00K 10-K · filed 2024-02-27 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $534.47K derived: sum of 2 quarters · filed 2013-03-11 | $535.00K 10-K · filed 2013-03-11 | ||
| 2012-09-30 | $534.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $535.00K 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $535.00 10-Q · filed 2012-08-08 | ||||
| 2012-03-15 | $535.00K 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |